ALDURAZYME Side Effects

7031079-9 | Chills, Cyanosis, Disease Progression, Headache, Hydrocephalus, Irritability, Mucopolysaccharidosis I, Oxygen Saturation Decreased, Pneumonia
on Sep 20, 2010 Female patient from COLOMBIA , child 5 years of age, weighting 35.27 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: chills, cyanosis, disease progression, headache (What is headache?), hydrocephalus (What is hydrocephalus?), irritability, mucopolysaccharidosis i, oxygen saturation decreased, pneumonia (What is pneumonia?). Aldurazyme dosage: 0.54 Mg/kg,. Patient was hospitalized.

7008743-0 | Diabetes Mellitus, Diabetic Nephropathy, Haemodialysis, Renal Failure
Patient was taking Aldurazyme (View Usage). Patient had the following side effects: diabetes mellitus, diabetic nephropathy, haemodialysis, renal failure on Sep 09, 2010 from BRAZIL Additional patient health information: Male patient , 19 years of age, . Aldurazyme dosage: . Patient was hospitalized.

7008741-7 | Adenoidal Hypertrophy, Pneumonia
Adverse event was reported on Sep 09, 2010 by a Male patient taking Aldurazyme (View Usage) (Dosage: 5.8 Mg, 1x/w) was diagnosed with mucopolysaccharidosis i and. Location: COLOMBIA , child 2 years of age, weighting 35.27 lb, After Aldurazyme was administered, patient had the following side effects: adenoidal hypertrophy, pneumonia (What is pneumonia?). Patient was hospitalized.

7008740-5 | Pulmonary Alveolar Haemorrhage
on Sep 13, 2010 Female patient from JAPAN , 51 years of age, weighting 103.6 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: pulmonary alveolar haemorrhage. Aldurazyme dosage: 26.1 Mg, 1x/w, Intravenous. During the same period patient was treated with WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ).


7007156-5 | Device Occlusion, Device Related Infection, Feeling Jittery, Heart Rate Increased, Infusion Related Reaction, Irritability, Pallor, Pyrexia, Staphylococcal Infection
on Aug 31, 2010 Male patient from CANADA , weighting 22.05 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). Patient had the following side effects: device occlusion, device related infection, feeling jittery, heart rate increased, infusion related reaction, irritability, pallor, pyrexia, staphylococcal infection (What is staphylococcal infection?). Aldurazyme dosage: 5.8 Mg. Patient was hospitalized.

7007154-1 | Disease Progression, Mucopolysaccharidosis I
Patient was taking Aldurazyme (View Usage). After Aldurazyme was administered, patient had the following side effects: disease progression, mucopolysaccharidosis i on Aug 30, 2010 from ARGENTINA Additional patient health information: Female patient , child 10 years of age, was diagnosed with mucopolysaccharidosis i and. Aldurazyme dosage: .

6973904-3 | Abasia, Cardio-respiratory Arrest, Developmental Delay, Diaphragmatic Hernia, Gastroenteritis, Infusion Related Reaction, Nausea, Pallor, Pyrexia
Adverse event was reported on Aug 24, 2010 by a Male patient taking Aldurazyme (View Usage) (Dosage: 0.58 Mg/kg, 1x/w, Intravenous) was diagnosed with mucopolysaccharidosis i and. Location: BRAZIL , child 8 years of age, weighting 44.09 lb, Patient experienced the following unwanted or unexpected effects: abasia, cardio-respiratory arrest, developmental delay, diaphragmatic hernia, gastroenteritis (What is gastroenteritis?), infusion related reaction, nausea (What is nausea?), pallor, pyrexia.

6969448-5 | Infusion Related Reaction, Pulmonary Alveolar Haemorrhage, Urticaria
on Aug 25, 2010 Female patient from JAPAN , 51 years of age, weighting 103.6 lb, was diagnosed with mucopolysaccharidosis and was treated with Aldurazyme (View Usage). Patient had the following side effects: infusion related reaction, pulmonary alveolar haemorrhage, urticaria. Aldurazyme dosage: 26.1 Mg, 1x/w, Intravenous.

6969434-5 | Abdominal Hernia, Acute Abdomen, Cardiac Failure, Hypovitaminosis, Malabsorption
on Aug 19, 2010 Female patient from GERMANY , 39 years of age, weighting 85.98 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). After Aldurazyme was administered, patient had the following side effects: abdominal hernia, acute abdomen, cardiac failure, hypovitaminosis, malabsorption. Aldurazyme dosage: Intravenous.

6963857-6 | Abasia, Developmental Delay, Gastroenteritis, Nausea, Pallor, Pyrexia, Respiratory Failure, Sinusitis
Patient was taking Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: abasia, developmental delay, gastroenteritis (What is gastroenteritis?), nausea (What is nausea?), pallor, pyrexia, respiratory failure, sinusitis (What is sinusitis?) on Aug 17, 2010 from BRAZIL Additional patient health information: Male patient , child 8 years of age, was diagnosed with mucopolysaccharidosis and. Aldurazyme dosage: Intravenous.

6960984-4 | Cervical Spinal Stenosis, Headache, Hypoaesthesia
Adverse event was reported on Aug 17, 2010 by a Female patient taking Aldurazyme (View Usage) (Dosage: 0.58 Mg/kg, 1x/w,) was diagnosed with mucopolysaccharidosis i and. Location: UNITED STATES , 49 years of age, weighting 116.8 lb, Patient had the following side effects: cervical spinal stenosis, headache (What is headache?), hypoaesthesia. During the same period patient was treated with COUMADIN (View Coumadin Review and Coumadin Label ), ALLEGRA (View Allegra Review and Allegra Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), CENESTIN (View Cenestin Review and Cenestin Label ), VALIUM (View Valium Review and Valium Label ), PERCOCET (View Percocet Review and Percocet Label ), HEPARIN (View Heparin Review and Heparin Label ). Patient was hospitalized.

6938475-6 | Abdominal Pain, Anxiety, Bronchial Hyperreactivity, Chills, Cough, Headache, Hypotension, Infusion Related Reaction, Nausea
on Aug 05, 2010 Female patient from FRANCE , 29 years of age, weighting 134.5 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). After Aldurazyme was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), anxiety (What is anxiety?), bronchial hyperreactivity, chills, cough, headache (What is headache?), hypotension, infusion related reaction, nausea (What is nausea?). Aldurazyme dosage: 37.7 Mg,. During the same period patient was treated with FLUINDIONE (FLUINDIONE) (View Fluindione (fluindione) Review and Fluindione (fluindione) Label ), LUTENYL (NOMEGESTROL ACETATE) (View Lutenyl (nomegestrol Acetate) Review and Lutenyl (nomegestrol Acetate) Label ).

6936106-2 | Adenovirus Infection, Coronary Artery Disease, Cytomegalovirus Infection, Gastrointestinal Haemorrhage, Haematemesis, Hepatic Function Abnormal, Mucosal Inflammation, Multi-organ Failure, Oedema
on Aug 04, 2010 Male patient from UNITED STATES , child 2 years of age, was diagnosed with mucopolysaccharidosis and was treated with Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: adenovirus infection, coronary artery disease (What is coronary artery disease?), cytomegalovirus infection (What is cytomegalovirus infection?), gastrointestinal haemorrhage, haematemesis, hepatic function abnormal, mucosal inflammation, multi-organ failure, oedema. Aldurazyme dosage: 8.7 Mg, 1x/w, Intravenous. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), BUSULPHAM (BUSULFAN) (View Busulpham (busulfan) Review and Busulpham (busulfan) Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), URSODIOL (View Ursodiol Review and Ursodiol Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ). Patient was hospitalized.

6929589-5 | Chorioretinal Atrophy, Papilloedema
Patient was taking Aldurazyme (View Usage). Patient had the following side effects: chorioretinal atrophy, papilloedema on Jul 30, 2010 from FRANCE Additional patient health information: Female patient , child 5 years of age, weighting 42.99 lb, was diagnosed with mucopolysaccharidosis i and. Aldurazyme dosage: 17.4 Mg,; 20.3 Mg,. During the same period patient was treated with CETIRIZINE HCL (View Cetirizine Hcl Review and Cetirizine Hcl Label ), PREDNISONE (View Prednisone Review and Prednisone Label ).

6916245-2 | Spinal Decompression
Adverse event was reported on Jul 29, 2010 by a Female patient taking Aldurazyme (View Usage) (Dosage: 0.58 Mg/kg, 1xw) was diagnosed with mucopolysaccharidosis i and. Location: UNITED STATES , 49 years of age, weighting 116.8 lb, After Aldurazyme was administered, patient had the following side effects: spinal decompression. Patient was hospitalized.

6887277-8 | Influenza, Urinary Glycosaminoglycans Increased
on Jul 12, 2010 Female patient from GREECE , 36 years of age, weighting 110.2 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: influenza, urinary glycosaminoglycans increased. Aldurazyme dosage: 0.58 Mg/kg, 1x/w, Intravenous. During the same period patient was treated with PANWARFIN (WARFARIN SODIUM) (View Panwarfin (warfarin Sodium) Review and Panwarfin (warfarin Sodium) Label ), FRUMIL (AMILORIDE HYDROCHLORIDE, FUROSEMIDE) (View Frumil (amiloride Hydrochloride, Furosemide) Review and Frumil (amiloride Hydrochloride, Furosemide) Label ), LOPRESSOR (View Lopressor Review and Lopressor Label ), ZIRTEK (CETIRIZINE HYDROCHLORIDE) (View Zirtek (cetirizine Hydrochloride) Review and Zirtek (cetirizine Hydrochloride) Label ), FENISTIL (DIMETINDENE MALEATE) (View Fenistil (dimetindene Maleate) Review and Fenistil (dimetindene Maleate) Label ).

6887269-9 | Disease Progression, Mucopolysaccharidosis Ih, Respiratory Failure
on Jul 16, 2010 Male patient from SPAIN , child 10 years of age, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). Patient had the following side effects: disease progression, mucopolysaccharidosis ih, respiratory failure. Aldurazyme dosage: Intravenous. Patient was hospitalized.

6874561-7 | Apallic Syndrome, Cardio-respiratory Arrest
Patient was taking Aldurazyme (View Usage). After Aldurazyme was administered, patient had the following side effects: apallic syndrome, cardio-respiratory arrest on Jul 10, 2010 from BRAZIL Additional patient health information: Female patient , 14 years of age, was diagnosed with mucopolysaccharidosis i and. Aldurazyme dosage: 1.2 Mg/kg, Q2w, Intravenous.

6862625-3 | Respiratory Failure
Adverse event was reported on Jul 05, 2010 by a Male patient taking Aldurazyme (View Usage) (Dosage: Intravenous) was diagnosed with mucopolysaccharidosis i and. Location: SPAIN , child 10 years of age, Patient experienced the following unwanted or unexpected effects: respiratory failure. Patient was hospitalized.

6861408-8 | Cardiac Disorder, Dehydration, Depression, Fatigue, Gastrointestinal Hypomotility, Hypernatraemia, Insomnia, Iron Deficiency, Pancreatitis
on Jul 02, 2010 Male patient from UNITED STATES , 29 years of age, weighting 66.80 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). Patient had the following side effects: cardiac disorder, dehydration, depression (What is depression?), fatigue, gastrointestinal hypomotility, hypernatraemia, insomnia, iron deficiency, pancreatitis. Aldurazyme dosage: 20.3 Mg, 1x/w, Intravenous. During the same period patient was treated with ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ).

6846990-9 | Influenza, Urinary Glycosaminoglycans Increased
on Jun 30, 2010 Female patient from GREECE , 36 years of age, weighting 110.2 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). After Aldurazyme was administered, patient had the following side effects: influenza, urinary glycosaminoglycans increased. Aldurazyme dosage: 0.58 Mg/kg, 1x/w, Intravenous. During the same period patient was treated with PANWARFIN (WARFARIN SODIUM) (View Panwarfin (warfarin Sodium) Review and Panwarfin (warfarin Sodium) Label ), FRUMIL (AMILORIDE HYDROCHLORIDE, FUROSEMIDE) (View Frumil (amiloride Hydrochloride, Furosemide) Review and Frumil (amiloride Hydrochloride, Furosemide) Label ), LOPRESSOR (View Lopressor Review and Lopressor Label ), ZIRTEK (CETIRIZINE HYDROCHLORIDE) (View Zirtek (cetirizine Hydrochloride) Review and Zirtek (cetirizine Hydrochloride) Label ), FENISTIL (DIMETINDENE MALEATE) (View Fenistil (dimetindene Maleate) Review and Fenistil (dimetindene Maleate) Label ).

6846989-2 | Bronchopneumonia
Patient was taking Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: bronchopneumonia on Jul 01, 2010 from COLOMBIA Additional patient health information: Male patient , child 2 years of age, weighting 28.66 lb, was diagnosed with mucopolysaccharidosis i and. Aldurazyme dosage: 0.44 Mg/kg, Qow, Intravenous; 0.44 Mg/kg,. Patient was hospitalized.

6844985-2 | Anaemia Haemolytic Autoimmune, Ascites, Diarrhoea, Hypervolaemia, Hypomagnesaemia, Irritability, Lethargy, Nausea, Nephrotic Syndrome
Adverse event was reported on Jun 28, 2010 by a Female patient taking Aldurazyme (View Usage) (Dosage: See Image) was diagnosed with mucopolysaccharidosis i, medical diet and. Location: UNITED STATES , child 3 years of age, weighting 29.98 lb, Patient had the following side effects: anaemia haemolytic autoimmune, ascites, diarrhoea, hypervolaemia, hypomagnesaemia, irritability, lethargy, nausea (What is nausea?), nephrotic syndrome. During the same period patient was treated with CYCLOSPORINE (60 Mg, Tid, Parenteral, 22 Mg, Tid, Intravenous) (View Cyclosporine Review and Cyclosporine Label ), SIMILAC (CARBOHYDRATES NOS, FATS NOS, LINOLEIC ACID, MINERALS NOS, PRO (View Similac (carbohydrates Nos, Fats Nos, Linoleic Acid, Minerals Nos, Pro Review and Similac (carbohydrates Nos, Fats Nos, Linoleic Acid, Minerals Nos, Pro Label ), PEPTAMEN (NUTRIENTS NOS) (View Peptamen (nutrients Nos) Review and Peptamen (nutrients Nos) Label ), BENADRYL (View Benadryl Review and Benadryl Label ), HYDROXYZINE (View Hydroxyzine Review and Hydroxyzine Label ). Patient was hospitalized.

6843024-7 | Blood Immunoglobulin G Increased, Bronchospasm, Cardiac Arrest, Cardiac Failure, Cardiac Failure Acute, Cardiogenic Shock, Cough, Disease Progression, Mucopolysaccharidosis Ih/s
on Jun 25, 2010 Female patient from BRAZIL , child 12 years of age, weighting 61.73 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). After Aldurazyme was administered, patient had the following side effects: blood immunoglobulin g increased, bronchospasm, cardiac arrest (What is cardiac arrest?), cardiac failure, cardiac failure acute, cardiogenic shock, cough, disease progression, mucopolysaccharidosis ih/s. Aldurazyme dosage: 33.6 Mg, 1x/w, Intravenous; 1.8 Mg/kg, Q2w, Intravenous. During the same period patient was treated with FUROSEMIDE (View Furosemide Review and Furosemide Label ). Patient was hospitalized.

6839119-4 | Hypertension
on Apr 30, 2010 Male patient from UNITED STATES , child 4 years of age, weighting 33.07 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: hypertension. Aldurazyme dosage: 8.7 Mg, 1x/w, Intravenous. Patient was hospitalized.

6822142-3 | Cardiac Arrest, Cardiac Failure, Cardiogenic Shock, Tracheobronchitis
Patient was taking Aldurazyme (View Usage). Patient had the following side effects: cardiac arrest (What is cardiac arrest?), cardiac failure, cardiogenic shock, tracheobronchitis on Jun 18, 2010 from BRAZIL Additional patient health information: Female patient , child 12 years of age, was diagnosed with mucopolysaccharidosis and. Aldurazyme dosage: 0.58 Mg/kg, 1x/w, Intravenous; 1.8 Mg/kg, Q2w, Intravenous. Patient was hospitalized.

6821204-4 | Influenza, Urinary Glycosaminoglycans Increased
Adverse event was reported on Jun 16, 2010 by a Female patient taking Aldurazyme (View Usage) (Dosage: 0.58 Mg/kg, 1x/w, Intravenous) was diagnosed with mucopolysaccharidosis i and. Location: GREECE , 36 years of age, weighting 110.2 lb, After Aldurazyme was administered, patient had the following side effects: influenza, urinary glycosaminoglycans increased. During the same period patient was treated with PANWARFIN (WARFARIN SODIUM) (View Panwarfin (warfarin Sodium) Review and Panwarfin (warfarin Sodium) Label ), FRUMIL (AMILORIDE HYDROCHLORIDE, FUROSEMIDE) (View Frumil (amiloride Hydrochloride, Furosemide) Review and Frumil (amiloride Hydrochloride, Furosemide) Label ), LOPRESSOR (View Lopressor Review and Lopressor Label ), ZIRTEK (CETIRIZINE HYDROCHLORIDE) (View Zirtek (cetirizine Hydrochloride) Review and Zirtek (cetirizine Hydrochloride) Label ), FENISTIL (DIMETINDENE MALEATE) (View Fenistil (dimetindene Maleate) Review and Fenistil (dimetindene Maleate) Label ).

6816291-3 | Anaemia, Blood Immunoglobulin G Increased, Fatigue, Gastrointestinal Hypomotility, Insomnia, Intestinal Dilatation, Iron Deficiency, Platelet Count Decreased, Red Blood Cell Count Decreased
on Jun 15, 2010 Male patient from UNITED STATES , 29 years of age, weighting 61.73 lb, was diagnosed with mucopolysaccharidosis and was treated with Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, blood immunoglobulin g increased, fatigue, gastrointestinal hypomotility, insomnia, intestinal dilatation, iron deficiency, platelet count decreased, red blood cell count decreased. Aldurazyme dosage: 20.3 Mg, 1x/w, Intravenous. During the same period patient was treated with ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ).

6801749-3 | Bronchospasm, Respiratory Failure
on Jun 10, 2010 Female patient from BRAZIL , child 4 years of age, was diagnosed with mucopolysaccharidosis and was treated with Aldurazyme (View Usage). Patient had the following side effects: bronchospasm, respiratory failure. Aldurazyme dosage: . During the same period patient was treated with SALBUTAMOL (SALBUTAMOL SULFATE) (View Salbutamol (salbutamol Sulfate) Review and Salbutamol (salbutamol Sulfate) Label ), CLENIL (BECLOMETASONE DIPROPIONATE) (View Clenil (beclometasone Dipropionate) Review and Clenil (beclometasone Dipropionate) Label ). Patient was hospitalized.

6800267-6 | Multi-organ Failure
Patient was taking Aldurazyme (View Usage). After Aldurazyme was administered, patient had the following side effects: multi-organ failure on Jun 01, 2010 from AUSTRALIA Additional patient health information: Male patient , child 2 years of age, was diagnosed with mucopolysaccharidosis i and. Aldurazyme dosage: 8.7 Mg, 1x/w, Intravenous.

6800049-5 | Bronchopneumonia
Adverse event was reported on Jun 09, 2010 by a Male patient taking Aldurazyme (View Usage) (Dosage: 0.44 Mg/kg; 0.44 Mg/kg) was diagnosed with mucopolysaccharidosis and. Location: COLOMBIA , child 2 years of age, weighting 28.66 lb, Patient experienced the following unwanted or unexpected effects: bronchopneumonia. Patient was hospitalized.

6800048-3 | Pneumonia, Sepsis
on Jun 03, 2010 Female patient from COLOMBIA , child 5 years of age, weighting 28.66 lb, was diagnosed with mucopolysaccharidosis and was treated with Aldurazyme (View Usage). Patient had the following side effects: pneumonia (What is pneumonia?), sepsis (What is sepsis?). Aldurazyme dosage: 1.5 Mg/kg, Qow. Patient was hospitalized.

6800047-1 |
on Jun 07, 2010 Male patient from ARGENTINA , child 8 years of age, was diagnosed with mucopolysaccharidosis and was treated with Aldurazyme (View Usage). . Aldurazyme dosage: 8.7 Mg.

6799008-0 | Nephrotic Syndrome, Renal Failure
Patient was taking Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: nephrotic syndrome, renal failure on Jun 01, 2010 from UNITED STATES Additional patient health information: Female patient , child 3 years of age, weighting 28.66 lb, was diagnosed with mucopolysaccharidosis i and. Aldurazyme dosage: See Image. Patient was hospitalized.

6791385-X | Cardiac Failure, Pneumonia, Pneumonia Viral, Respiratory Failure, Stem Cell Transplant
Adverse event was reported on Jun 08, 2010 by a Male patient taking Aldurazyme (View Usage) (Dosage: 8.7 Mg, Unk, Intravenous) was diagnosed with mucopolysaccharidosis i and. Location: JAPAN , weighting 24.25 lb, Patient had the following side effects: cardiac failure, pneumonia (What is pneumonia?), pneumonia viral, respiratory failure, stem cell transplant. During the same period patient was treated with CYPROHEPTADINE HCL (View Cyproheptadine Hcl Review and Cyproheptadine Hcl Label ), TRICHLORETHYL PHOSPHATE SODIUM (TRICHLORETHYL PHOSPHATE SODIUM) (View Trichlorethyl Phosphate Sodium (trichlorethyl Phosphate Sodium) Review and Trichlorethyl Phosphate Sodium (trichlorethyl Phosphate Sodium) Label ), POVIDONE IODINE (View Povidone Iodine Review and Povidone Iodine Label ), POTASSIUM CHLORIDE (View Potassium Chloride Review and Potassium Chloride Label ), SODIUM CHLORIDE 0.9% (View Sodium Chloride 0.9% Review and Sodium Chloride 0.9% Label ), FOSCARNET SODIUM (View Foscarnet Sodium Review and Foscarnet Sodium Label ), DEXTROSE 5% (View Dextrose 5% Review and Dextrose 5% Label ), MANGANESE CHLORIDE (MANGANESE CHLORIDE) (View Manganese Chloride (manganese Chloride) Review and Manganese Chloride (manganese Chloride) Label ). Patient was hospitalized.

6770389-7 | Pneumonia Moraxella
on May 25, 2010 Female patient from UNITED STATES , 15 years of age, weighting 93.04 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). After Aldurazyme was administered, patient had the following side effects: pneumonia moraxella. Aldurazyme dosage: 23.2 Mg, 1x/w, Intravenous. Patient was hospitalized.

6769508-8 | Cardiac Failure, Interstitial Lung Disease, Pneumonia, Pneumonia Viral, Respiratory Failure, Stem Cell Transplant
on May 25, 2010 Male patient from JAPAN , weighting 24.25 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac failure, interstitial lung disease, pneumonia (What is pneumonia?), pneumonia viral, respiratory failure, stem cell transplant. Aldurazyme dosage: 8.7 Mg. During the same period patient was treated with CYPROPHETADINE HYDROCHLORIDE (CYPROHEPTADINE HYDROCHLORIDE) (View Cyprophetadine Hydrochloride (cyproheptadine Hydrochloride) Review and Cyprophetadine Hydrochloride (cyproheptadine Hydrochloride) Label ), TRICHLORETHYL PHOSPHATE SODIUM (TRICHLORETHYL PHOSPHATE SODI (View Trichlorethyl Phosphate Sodium (trichlorethyl Phosphate Sodi Review and Trichlorethyl Phosphate Sodium (trichlorethyl Phosphate Sodi Label ), POVIDONE IODINE (View Povidone Iodine Review and Povidone Iodine Label ), POTASSIUM CHLORIDE (View Potassium Chloride Review and Potassium Chloride Label ), SODIUM CHLORIDE 0.9% (View Sodium Chloride 0.9% Review and Sodium Chloride 0.9% Label ), FOSCARNET SODIUM (View Foscarnet Sodium Review and Foscarnet Sodium Label ), DEXTROSE 5% (View Dextrose 5% Review and Dextrose 5% Label ), MANGANESE CHLORIDE (MANGANESE CHLORIDE) (View Manganese Chloride (manganese Chloride) Review and Manganese Chloride (manganese Chloride) Label ). Patient was hospitalized.

6768274-X |
Patient was taking Aldurazyme (View Usage). on May 28, 2010 from ARGENTINA Additional patient health information: Male patient , child 8 years of age, was diagnosed with mucopolysaccharidosis and. Aldurazyme dosage: 8.7 Mg.

6768273-8 | Lung Infection, Respiratory Failure
Adverse event was reported on May 28, 2010 by a Male patient taking Aldurazyme (View Usage) (Dosage: 0.58 Mg/kg, 1x/w, Intravenous) was diagnosed with mucopolysaccharidosis and. Location: TURKEY , child 4 years of age, weighting 39.68 lb, After Aldurazyme was administered, patient had the following side effects: lung infection, respiratory failure.

6753860-3 | Aortic Valve Disease, Aortic Valve Incompetence
on May 20, 2010 Female patient from GREECE , 30 years of age, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: aortic valve disease, aortic valve incompetence. Aldurazyme dosage: 0.58 Mg/kg, 1x/w, Intravenous . During the same period patient was treated with COUMADIN (View Coumadin Review and Coumadin Label ).

6753784-1 | Infection, Pneumonia
on May 18, 2010 Female patient from COLOMBIA , child 5 years of age, weighting 28.66 lb, was diagnosed with mucopolysaccharidosis and was treated with Aldurazyme (View Usage). Patient had the following side effects: infection (What is infection?), pneumonia (What is pneumonia?). Aldurazyme dosage: 1.5 Mg/kg,qow. Patient was hospitalized.

6753781-6 | Bronchopneumonia
Patient was taking Aldurazyme (View Usage). After Aldurazyme was administered, patient had the following side effects: bronchopneumonia on May 20, 2010 from COLOMBIA Additional patient health information: Male patient , child 2 years of age, weighting 28.66 lb, was diagnosed with mucopolysaccharidosis i and. Aldurazyme dosage: 0.44 Mg/kg. Patient was hospitalized.

6740308-8 | Cardiac Failure, Interstitial Lung Disease, Pneumonia, Respiratory Failure
Adverse event was reported on May 07, 2010 by a Male patient taking Aldurazyme (View Usage) (Dosage: 8.7 Mg) was diagnosed with mucopolysaccharidosis i and. Location: JAPAN , weighting 24.25 lb, Patient experienced the following unwanted or unexpected effects: cardiac failure, interstitial lung disease, pneumonia (What is pneumonia?), respiratory failure. During the same period patient was treated with CYPROHEPTADINE HCL (View Cyproheptadine Hcl Review and Cyproheptadine Hcl Label ), TRICHLORETHYL PHOSPHATE SODIUM (TRICHLORETHYL PHOSPHATE SODIUM) (View Trichlorethyl Phosphate Sodium (trichlorethyl Phosphate Sodium) Review and Trichlorethyl Phosphate Sodium (trichlorethyl Phosphate Sodium) Label ), POVIDONE IODINE (View Povidone Iodine Review and Povidone Iodine Label ), POTASSIUM CHLORIDE (View Potassium Chloride Review and Potassium Chloride Label ), SODIUM CHLORIDE 0.9% (View Sodium Chloride 0.9% Review and Sodium Chloride 0.9% Label ), FOSCARNET SODIUM (View Foscarnet Sodium Review and Foscarnet Sodium Label ), DEXTROSE 5% (View Dextrose 5% Review and Dextrose 5% Label ), MANGANESE CHLORIDE (MANGANESE CHLORIDE) (View Manganese Chloride (manganese Chloride) Review and Manganese Chloride (manganese Chloride) Label ). Patient was hospitalized.

6740253-8 | Aortic Valve Replacement, Cardiac Failure, Mitral Valve Replacement, Oedema
on May 07, 2010 Female patient from BRAZIL , 19 years of age, weighting 92.59 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). Patient had the following side effects: aortic valve replacement, cardiac failure, mitral valve replacement, oedema. Aldurazyme dosage: . Patient was hospitalized.

6735281-2 | Dehydration, Hypernatraemia, Pancreatitis, Psychotic Disorder, Weight Decreased
on May 04, 2010 Male patient from UNITED STATES , 28 years of age, weighting 66.14 lb, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). After Aldurazyme was administered, patient had the following side effects: dehydration, hypernatraemia, pancreatitis, psychotic disorder (What is psychotic disorder?), weight decreased. Aldurazyme dosage: 20 Mg, 1x/w, Intravenous. During the same period patient was treated with MESTINON (View Mestinon Review and Mestinon Label ), REMERON (View Remeron Review and Remeron Label ), PEPCID (View Pepcid Review and Pepcid Label ), LACTOBACILLUS (LACTOBACILLUS ACIDOPHILUS) (View Lactobacillus (lactobacillus Acidophilus) Review and Lactobacillus (lactobacillus Acidophilus) Label ), KEPPRA (View Keppra Review and Keppra Label ), METRONIDAZOLE (View Metronidazole Review and Metronidazole Label ), POTASSIUM CHLORIDE (View Potassium Chloride Review and Potassium Chloride Label ). Patient was hospitalized.

6735268-X | Pneumonia
Patient was taking Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: pneumonia (What is pneumonia?) on May 05, 2010 from UNITED STATES Additional patient health information: Female patient , 15 years of age, weighting 88.18 lb, was diagnosed with mucopolysaccharidosis i and. Aldurazyme dosage: 23.2 Mg, 1x/w, Intravenous. Patient was hospitalized.

6735260-5 | Anaemia, Blood Immunoglobulin G, Fatigue, Gastrointestinal Hypomotility, Insomnia, Intestinal Dilatation, Iron Deficiency, Malnutrition, Platelet Count Decreased
Adverse event was reported on May 04, 2010 by a Male patient taking Aldurazyme (View Usage) (Dosage: 20 Mg, 1x/w, Intravenous) was diagnosed with mucopolysaccharidosis i and. Location: UNITED STATES , 29 years of age, weighting 61.73 lb, Patient had the following side effects: anaemia, blood immunoglobulin g, fatigue, gastrointestinal hypomotility, insomnia, intestinal dilatation, iron deficiency, malnutrition, platelet count decreased. During the same period patient was treated with ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ).

6718572-0 | Corneal Transplant
on Apr 27, 2010 Male patient from UNITED STATES , 18 years of age, weighting 174.2 lb, was diagnosed with mucopolysaccharidosis and was treated with Aldurazyme (View Usage). After Aldurazyme was administered, patient had the following side effects: corneal transplant. Aldurazyme dosage: 47 Mg, 1x/w, Intravenous.

6718571-9 | Asthma, Carpal Tunnel Syndrome, Chills, Flushing, Headache, Intracranial Pressure Increased, Nausea, Neurosensory Hypoacusis, Respiratory Disorder
on Apr 26, 2010 Female patient from UNITED STATES , 27 years of age, was diagnosed with mucopolysaccharidosis i and was treated with Aldurazyme (View Usage). Patient experienced the following unwanted or unexpected effects: asthma (What is asthma?), carpal tunnel syndrome (What is carpal tunnel syndrome?), chills, flushing, headache (What is headache?), intracranial pressure increased, nausea (What is nausea?), neurosensory hypoacusis, respiratory disorder. Aldurazyme dosage: 0.58 Mg/kg, 1x/w, Intravenous, Intrathecal. During the same period patient was treated with LASIX (View Lasix Review and Lasix Label ), TOPROL XL (View Toprol-xl Review and Toprol-xl Label ), ACETAZOLAMIDE (ACETAZOLOMIDE) (View Acetazolamide (acetazolomide) Review and Acetazolamide (acetazolomide) Label ), MAGNESIUM (MAGNESIUM OXIDE) (View Magnesium (magnesium Oxide) Review and Magnesium (magnesium Oxide) Label ), AVINZA (View Avinza Review and Avinza Label ), DIGESTIVES, INCL ENZYMES (View Digestives, Incl Enzymes Review and Digestives, Incl Enzymes Label ), FISH OIL (FISH OIL) (View Fish Oil (fish Oil) Review and Fish Oil (fish Oil) Label ).

6713913-2 | Cardiac Failure
Patient was taking Aldurazyme (View Usage). Patient had the following side effects: cardiac failure on Apr 28, 2010 from BRAZIL Additional patient health information: Female patient , 17 years of age, was diagnosed with mucopolysaccharidosis i and. Aldurazyme dosage: . Patient was hospitalized.